Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators
摘要:
We report the discovery and optimization of a novel series of dihydrobenzofuran amides as gamma-secretase modulators (GSMs). Strategies for aligning in vitro potency with drug-like physicochemical properties and good microsomal stability while avoiding P-gp mediated efflux are discussed. Lead compounds such as 35 and 43 have moderate to good in vitro potency and excellent selectivity against Notch. Good oral bioavailability was achieved as well as robust brain A beta 42 lowering activity at 100 mg/kg po dose. (C) 2012 Elsevier Ltd. All rights reserved.
[EN] NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OSTEOPOROSIS<br/>[FR] NOUVEAUX ANTAGONISTES TRICYCLIQUES DU RÉCEPTEUR SENSIBLE AU CALCIUM POUR LE TRAITEMENT DE L'OSTÉOPOROSE
申请人:MERCK SHARP & DOHME
公开号:WO2015089842A1
公开(公告)日:2015-06-25
Novel tricyclic compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing osteoporosis and similar conditions. The compounds are effective as calcium sensing receptor antagonists. Pharmaceutical compositions and methods of treatment are also included.